IWF Price Performance: IWF's 52-week price range is between $308.67 and $493, with the last trade recorded at $475.44, which is compared to its 200-day moving average for technical analysis.
ETFs Trading Mechanism: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand, impacting the underlying holdings.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), which can affect the individual components within the ETFs.
Author's Views Disclaimer: The opinions expressed in the article are solely those of the author and do not necessarily represent the views of Nasdaq, Inc.
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 942.83 USD with a low forecast of 880.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 942.83 USD with a low forecast of 880.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 823.250
Low
880.00
Averages
942.83
High
1000.00
Current: 823.250
Low
880.00
Averages
942.83
High
1000.00
Deutsche Bank
George Hill
Buy
maintain
$861 -> $904
2025-12-10
Reason
Deutsche Bank
George Hill
Price Target
$861 -> $904
AI Analysis
2025-12-10
maintain
Buy
Reason
Deutsche Bank analyst George Hill raised the firm's price target on McKesson to $904 from $861 and keeps a Buy rating on the shares. The company reiterated plans to exit the its med-surgical business segment through an initial public offering, followed by a spin-off or split-off, with the separation being complete by the end of 2027, the analyst tells investors in a research note. The firm says that while the transaction is likely dilutive, the stock "can still perform through the transaction."
Barclays
Overweight
initiated
$960
2025-12-08
Reason
Barclays
Price Target
$960
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of McKesson with an Overweight rating and $960 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MCK
Unlock Now
Wells Fargo
Equal Weight
maintain
$816 -> $914
2025-11-10
Reason
Wells Fargo
Price Target
$816 -> $914
2025-11-10
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on McKesson to $914 from $816 and keeps an Equal Weight rating on the shares. The firm is updating its model following Q2 2026 earnings and increasing its tests following core pharma distribution and prescription technology strength.
Mizuho
Neutral
maintain
$770 -> $880
2025-11-07
Reason
Mizuho
Price Target
$770 -> $880
2025-11-07
maintain
Neutral
Reason
Mizuho raised the firm's price target on McKesson to $880 from $770 and keeps a Neutral rating on the shares.
About MCK
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
